ALK and non-small cell lung carcinoma: A previous study confirmed that identifying resistant ALK secondary mutations is essential in ALK fusion-positive NSCLC patients progressing after ALK-TKI therapy, as it can influence sensitivity to subsequent ALK-TKIs (36).